Introduction
============

Lumbar disc herniation (LDH) is a common disease in clinical practice, characterized by recurrent low back pain, with or without lower limb radicular pain, numbness, and intermittent claudication. In a case of severe LDH, muscle strength is decreased and bowel and bladder dysfunction occurs. The symptoms recur and are aggrevated by time; severe pain and long-term movement disorder cause physiological and psychological problems that affect the quality of life of patients.[@b1-jpr-11-1531] Therefore, relieving the pain symptoms and promoting functional recovery of lumbar vertebrae are the primary goals that have gained increased attention.

Lumbago and leg pain is common; approximately 70% of individuals experience low back pain with different severities throughout their lives.[@b2-jpr-11-1531] LDH has a high prevalence of 1.6%--13.4% and a lifetime prevalence of 12.2%--43%.[@b3-jpr-11-1531] In clinical practice, some patients present with residual lumbago and leg pain after lumbar disc surgery. Consequently, the nerve compression has been relieved by surgery, and therefore, pain is not caused simply by mechanical compression, and the primary reason might be tissue trauma and local inflammatory response. A study found that the long-term efficacy in LDH surgery group was not superior to that of conventional non-operative treatment group after 2 years of follow-up.[@b4-jpr-11-1531] Therefore, minimally invasive treatment is the main development direction for the treatment of LDH via various methods. The characteristics of the method include less trauma, quick recovery, and cost-efficiency, and hence, easily accepted by most patients; moreover, comprehensive therapy could also be adopted.

Transforaminal epidural steroid injection (TFESI) is a classical, minimally invasive treatment for radicular pain with a definite short-term efficacy, and the pain relief or functional recovery outcome is more robust at 2 weeks than 2 months;[@b5-jpr-11-1531],[@b6-jpr-11-1531] however, the medium- and long-term efficacy is controversial due to drug metabolism. Unlike conventional continuous radio frequency (CRF), the radio frequency (RF) current of pulsed radio frequency (PRF) is temporarily discontinuous and the heat dissipation in 480 ms intermittent period makes the tip temperature \<42°C, which does not destroy the structure of nerve fibers and maintains the integrity of function.[@b7-jpr-11-1531] Also, it does not cause hypesthesia, skin numbness, or dyskinesia. Presently, PRF is widely used in the treatment of neuralgia, stubborn low back pain, and joint pain;[@b8-jpr-11-1531]--[@b10-jpr-11-1531] however, some investigators also pursue a wait-and-see attitude toward the efficacy of PRF, and hence, further observation is recommended.

In addition, most of the PRF treatment points for lumbago and leg pain caused by LDH have been dorsal root ganglion (DRG) or lumbar disc;[@b11-jpr-11-1531] however, PRF does not injure the nerve and is very safe, and thus, spinal nerve root can be chosen as a therapeutic target. Therefore, in the present study, the efficacy and safety of CT-guided TFESI combined with PRF on spinal nerve root were assessed for the treatment of LDH.

Methods
=======

Patients
--------

A total of 135 patients with LDH, treated at the Department of Pain Management, Shengjing Hospital of China Medical University between January 2014 and December 2016, were selected. The study was approved by the Ethics Committee of Shengjing Hospital Affiliated to China Medical University. All patients were divided into three groups according to the order of entry (n=45): group A (TFESI), group B (PRF on spinal nerve root), and group C (TFESI combined with PRF on spinal nerve root) ([Figure 1](#f1-jpr-11-1531){ref-type="fig"}). All the patients received regular therapy before treatment, and all the responsible segments were treated.

The inclusion criteria for the patients were as follows: 1) radicular pain in lower extremities, with or without lower back pain; 2) CT or MRI showed herniated disk; however, the herniated nucleus pulposus was still wrapped by annulus fibrosus or a posterior longitudinal ligament without free fragment shedding; 3) the remission of the symptoms was not obvious after conservative treatments such as inactivity, drug, and physical therapy; and 4) patients rejected or were intolerant to surgery and required minimally invasive treatment.

Exclusion criteria: 1) puncture site was infected; 2) vertebral canal and intervertebral foramen were severely narrow, nerve root compression, ≥ grade 2 spondylolisthesis, lumbar inflammation, tuberculosis, tumor, and definite other intraspinal lesions; 3) severe neurological deficit, such as bowel and bladder dysfunction and progressive dyskinesia; 4) pregnancy; 5) abnormal coagulation index, severe hematopathy, abnormal liver and kidney function, or cardiopulmonary disease; and 6) poor blood-glucose control in diabetic patients or those with mental illness who were unable to co-operate with the treatment. All patients provided written informed consent before treatment regarding the associated risks and complications.

Methods of treatment
--------------------

The responsible segments were determined according to the symptoms, physical examinations, and imaging examinations, and multisegmental treatment was performed. Patients were placed in the prone position for the CT-guided segment scanning. Consecutively, puncture point, depth, and angle were marked after the RF cannula needle was slowly inserted under the guidance of CT, the tip of the needle was located in the intervertebral foramen, the RF electrode was inserted, and the RF test (Baylis Medical Inc., Montreal, Canada) was conducted. The RF was set at 50 Hz and 0.1--0.3 V to stimulate the sensory nerve; numbness and radicular pain were consistent with the painful area of the primary complaint. The RF was set at 2 Hz and 0.4--1.0V to test the motor nerve, and mild exercise was effectuated in the waist and gluteal muscles; also, muscle tremor and pulsation of the lower limbs occurred. The patients in group A were treated with TFESI, and 2.5 mL analgesic solution (2% lidocaine 5 mL + VitB12 1 mg + compound betamethasone 5 mg + normal saline 2 mL) was injected. The patients in group B were treated with PRF at 42°C for 300 seconds (pulse width 20 ms), and 2.5 mL solution (2% lidocaine 5 mL + VitB12 1 mg + normal saline 3 mL) was injected. The patients in group C were treated with PRF with the same parameters as group B and TFESI as group A. Finally, the needle was pulled out and the puncture point pressed. If patients did not present any adverse reactions, they could return to their wards.

Efficacy assessment and follow-up
---------------------------------

Patients were assessed before treatment as well as on day 1, day 14 and 1, 3, and 6 months after treatment. Patients were followed-up by nonsurgical group medical staff using the double-blind method. Visual analog scale (VAS): judged the degree of pain: no pain (0) and unbearable pain (10 points).Oswestry disability index (ODI): assessed the degree of disability and pain. ODI consisted of ten items including pain intensity, self-care, lifting, walking, sitting, standing, interfering with sleep, sex life, social life, and tourism. Each item had six options and was scored as 0--5 points. The sum of scores was expressed as a percentage: 0% represented no pain or disability, while 100% represented the most severe pain and disability.Global perceived effect (GPE): assessed the satisfaction: a) unsatisfied: GPE ≤4, symptoms were not changed or worse; b) satisfied: 4\< GPE ≤5, symptoms were improved; and c) very satisfied: GPE ≥6, symptoms were improved distinctly or patients recovered ([Table 1](#t1-jpr-11-1531){ref-type="table"}). Success was defined as score ≥6 (6 or 7 on a 7-point Likert scale).

Statistical analysis
====================

SPSS version 18.0 software was used for statistical analysis. Chi-squared test was used for the analysis of the enumeration data. When the sample size was small, Fisher's exact test was used. Kolmogorov--Smirnov test was used for the normal measurement data. The variables of normal distribu tion were expressed as mean ± SD, while the variables that did not conform to normal distribution were expressed as median ± interquartile range. For comparison of the variables of normal distribution, single factor analysis of variance was used, while least significant difference was used for pairwise comparison. On the other hand, the comparison of the variables that did not conform to normal distribution was conducted by Kruskal--Wallis test, and Mann--Whitney *U* test was used for pairwise comparison. *P*\<0.05 was considered a significant difference.

Results
=======

Preoperative general condition of patients
------------------------------------------

A total of 135 patients were enrolled. No statistical difference was observed in the general preoperative conditions including gender, age, preoperative pain duration, pain position, and preoperative VAS among the three groups (*P*\>0.05). The severity of pain in the three groups before treatment was categorized into different degrees based on the analgesic drugs used by patients with different pain scale, and no statistical difference was observed in the scale classification (*P*\>0.05) ([Table 2](#t2-jpr-11-1531){ref-type="table"}).

Intraoperative condition of patients
------------------------------------

The treatments were performed successfully in all patients. CT was used for positioning at a definite angle and depth. The tip of the needle was observed at the spinal nerve root in plain CT scan images. Three-dimensional CT showed that multiple RF needles were localized at the spinal nerve root of the lumbar intervertebral foramen, and sensory and motor tests could induce symptoms that were consistent with the preoperative range. No severe complications, such as spinal injury and paraplegia, occurred in the patients in the three groups due to CT guidance ([Figure 2](#f2-jpr-11-1531){ref-type="fig"}). The complications were mild and reversible and resolved within 3 months.

VAS score
---------

At every point of observation, the postoperative low back pain and lower limb radicular pain (VAS score) decreased in the three groups and differed significantly compared to before treatment (*P*\<0.05). Groups A and C showed a rapid analgesic effect and VAS score decreased 1 day post-treatment, which was statistically different from that in group B (*P*\<0.05); however, the maintenance time of analgesia effect in group A was short, and the onset of effect in group B was slow. The VAS scores in group A at 3 and 6 months after treatment were significantly higher than that in the other two groups (*P*\<0.05), while in groups B and C, the pain relief could be maintained for a prolonged period. The VAS scores in group C at 14 days and 1 month after treatment were significantly lower than that in the other two groups (*P*\<0.05). However, at 3 and 6 months after treatment, no statistical difference was observed in the VAS scores between groups B and C (*P*\>0.05) ([Figure 3](#f3-jpr-11-1531){ref-type="fig"}).

Degree of disability (ODI)
--------------------------

At every time point of observation, the quality of life in the three groups was improved after treatment, and the ODI score decreased, which differed significantly from that before treatment (*P*\<0.05). Groups A and C showed a rapid improvement in the quality of life and ODI score decreased 1 day after treatment, which was statistically different from that in group B (*P*\<0.05). However, the maintenance time of the improved quality of life in group A was short, and the onset of effect in group B was slow. On the other hand, the ODI scores in group A at 3 and 6 months after treatment were significantly higher than that in the other two groups (*P*\<0.05), while in groups B and C, the quality of life could be improved for a prolonged period. The ODI scores in group C at 14 days and 1 month after the treatment were significantly lower than that in the other two groups (*P*\<0.05). However, at 3 and 6 months post-treatment, no significant difference was observed in the ODI scores between groups B and C (*P*\>0.05) ([Table 3](#t3-jpr-11-1531){ref-type="table"}).

Satisfaction (GPE)
------------------

The percentage of patients with GPE ≥6 was shown in [Table 4](#t4-jpr-11-1531){ref-type="table"}. The GPE in group A decreased with time; it was significantly lower at 3 and 6 months after treatment than that in the other two groups (*P*\<0.05). The GPE in group B at 1 day after treatment was significantly lower than that in groups A and C (*P*\<0.05). Subsequently, the GPE increased gradually and reached a peak at 3 months after treatment, although statistical difference was not observed at 3 and 6 months after treatment between groups B and C (*P*\>0.05). The GPE in group C was higher in the early days, while that at 14 days and 1 month after treatment was significantly higher than that in the other two groups (*P*\<0.05); no significant difference was observed in the GPE at 3 and 6 months after treatment between groups B and C (*P*\>0.05) ([Table 4](#t4-jpr-11-1531){ref-type="table"}).

Discussion
==========

LDH is one of the most common causes of low back pain and radicular pain, which is easily overlooked; it is stubborn and affects the daily life of patients. Therefore, there is an urgent need to alleviate the pain and improve the quality of life of these patients.

Presently, several methods are available for LDH treatment that primarily encompass surgery and non-surgical treatment. Although the non-surgical treatment is of great significance, it requires a prolonged duration, has a poor curative effect, and relapse occurs frequently. On the other had, with surgery, trauma is significant, recovery is slow, and it might cause severe complications.[@b12-jpr-11-1531] Minimally invasive interventional therapy has been widely used in the treatment of chronic pain, and it has gradually become the developmental direction for the treatment of chronic lumbago and leg pain. Each minimally invasive interventional therapy has limitations, and the success rate varies greatly. Single therapy often has poor efficacy, and hence, it is necessary to select the patients accurately; comprehensive treatment could achieve the best results. Accurate CT scanning in therapy can be used to locate and determine the position of the needle tip. The present study accurately selected the inclusion and exclusion criteria. Physical compression caused by the free lumbar nucleus pulposus, severe stenosis of the spinal canal and intervertebral foramen, and definite nerve root bone compression should be resolved as a priority, otherwise, minimally invasive procedures would be ineffective.

The mechanisms underlying low back pain and radicular pain caused by LDH are yet to be elucidated. Mechanical pressure could lead to nerve injury and functional alteration. Although, after oppression caused by LDH was relieved by surgery, some patients did not show any improvement in symptoms. Thus, in addition to mechanical oppression, nerve root inflammatory response also played a critical role.[@b13-jpr-11-1531]--[@b15-jpr-11-1531] Steroids exert anti-inflammatory and immunosuppressive effects, and intervertebral foramen injection was administered directly to the nerve root, which relieved the pain markedly;[@b16-jpr-11-1531],[@b17-jpr-11-1531] however, the maintenance time was short. The present study found that all three treatments could effectively alleviate lower back pain and lower extremity radicular pain, which could improve the quality of life and increase the degree of satisfaction in patients. However, at 3 and 6 months after TFESI (Group A), VAS and ODI scores were significantly higher than those of the other two groups (*P*\<0.05), while GPE was lower than those of the other two groups (*P*\<0.05). At day 1, day 14, and 1 month after treatment, VAS and ODI scores in the combination group (Group C) were significantly lower than that in the PRF group (Group B) (*P*\<0.05). This early analgesic effect was associated with the anti-inflammatory effect of steroid injection, which could improve function in the patient at an early stage as well as the compliance of the patient. In groups B and C, pain relief could be maintained for a prolonged period. PRF affected neuromodulation in the spinal nerve root, which achieved a long-term analgesic effect. TFESI combined with PRF displayed the characteristics of rapid onset and prolonged maintenance; the overall efficacy was superior to that of the single method treatment.

The pulse current of PRF stimulated the nerve for regulation and relieved the pain after nerve injury.[@b18-jpr-11-1531] The present study found that the pain relief, improvement of quality of life, and increased satisfaction in PRF and combination groups could be maintained for up to 6 months. In group C, the patients returned to activity or work in 2--3 weeks. Due to few side effects of treatment, the patient could be active 1 day after treatment. Some studies reported the DRG PRF treatment with maximal safety at 42°C as compared to that of the conventional CRF therapy.[@b19-jpr-11-1531] Moreover, it relieved acute nerve root pain[@b20-jpr-11-1531] for a prolonged period.[@b21-jpr-11-1531] L-2 DRG PRF treatment was used for chronic lower back pain with or without pain in the lower extremities -- pain relief in patients without pain in the lower extremities was maintained up to 3 months. On the other hand, pain relief could be maintained for 1 month in patients with pain in the lower extremities; a medium-term remission was achieved.[@b22-jpr-11-1531],[@b23-jpr-11-1531] VAS, Neck Disability Index, and ODI scores were significantly decreased, suggesting that L-2 DRG PRF treatment had the same effect as TFESI;[@b24-jpr-11-1531] however, for lumbar nerve root pain due to different causes, PRF was more effective in herniated disc and spinal stenosis than failed back surgery syndrome.[@b25-jpr-11-1531] PRF treatment of the intervertebral disc could reduce the numeric rating scale score, improve the Roland-Morris disability questionnaire score, and alleviate chronic lumbar discogenic low back pain.[@b11-jpr-11-1531] One year after the PRF treatment of lumbar degenerative disc pain, the number of patients with \>50% pain relief reached 56%.[@b26-jpr-11-1531] As compared to intradiscal electrothermal therapy (IDET), patients were followed-up for 6 months, and no significant difference was observed between the PRF and IDET groups.[@b27-jpr-11-1531] Also, VAS and ODI scores were decreased, sitting tolerance time was increased, and the treatment was effective; however, the efficacy was limited.[@b28-jpr-11-1531] In the present study, the therapeutic sites of PRF were mostly intervertebral discs or DRG, and only a few studies are available on the effect on the spinal nerve root.[@b29-jpr-11-1531]--[@b31-jpr-11-1531] When PRF exerted an effect on DRG, the morphology was observed. As a result, the cell morphology was found to be normal under the light microscope, while the ultrastructural changes could be observed only under an electron microscope. These changes were subclinical and reversible. The accumulation of endoplasmic reticulum and the increase in the number of vacuoles in the cytoplasm could be observed in ganglion cells, which could selectively act on the neuronal axons of the small-diameter C, and Aδ nociceptive fibers could be affected selectively,[@b32-jpr-11-1531] unmyelinated axons were normal, and the Schwann cell membranes were completed.[@b19-jpr-11-1531],[@b33-jpr-11-1531] Therefore, the regulation of PRF on the nerve did not cause damage, and the biological effect was not related to the thermal injury. Consequently, a normal neural structure was maintained, and the PRF treatment could be carried out for the spinal nerve root.

Nevertheless, the underlying mechanism of alleviating pain with PRF was yet unclear. A recent study found that PRF enhanced the expression of anti-inflammatory factor GABAB-R1, Na/K-ATPase, and 5-HT3r in DRG, decreased the expression of proinflammatory factors TNF-α and IL-6, increased the expression of Na/K-ATPase in the spinal cord, and decreased the neurogenic inflammatory response. This phenomenon reduced the peripheral and central sensitization,[@b34-jpr-11-1531] inhibited the activation of MAPK in the spinal cord, reduced the release of cytokines, reduced the release of excitatory amino acid,[@b35-jpr-11-1531] inhibited the JNK activation in the spinal cord dorsal horn,[@b36-jpr-11-1531] and inhibited the sensitization of the spinal cord, thereby alleviating acute pain and improving neuropathic pain.[@b37-jpr-11-1531] In the rat LDH model, PRF DRG reduced the mechanical pain, the activity of microglia, and the expression of pERK.[@b38-jpr-11-1531] Moreover, PRF was carried out in the sacral epidural, which downregulated the activity of microglia at the level of intervertebral disc herniation and adjacent lumbar vertebrae, as well as, decreased the expression of CGRP.[@b39-jpr-11-1531] Therefore, the long-term analgesic effect of PRF might be associated with neuromodulation.[@b40-jpr-11-1531]

Conclusion
==========

TFESI combined with PRF for the treatment of LDH could effectively and rapidly relieve lumbago and radicular pain, reduce VAS and ODI scores, relieve pain symptoms, improve the quality of life, cure rate, and satisfaction of patients, as well as, achieve long-term remission. This treatment could be applied widely; however, the precise selection of patients is imperative.
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![Schematic illustration of the study design.\
**Note:** All 135 patients were included in the treatment.\
**Abbreviations:** TFESI, transforaminal epidural steroid injection; PRF, pulsed radio frequency.](jpr-11-1531Fig1){#f1-jpr-11-1531}

![CT guidance.\
**Notes:** (**A**) Puncture site was determined by CT scan, and was located at the spinal nerve root, as indicated by the arrow; (**B**) CT scan showed that the radio frequency needle was located at the spinal nerve root on the left side, as indicated by the arrow; and (**C**) three-dimensional CT reconstruction showed multisegmental intervertebral foramen needle shadow, as indicated by the arrow.](jpr-11-1531Fig2){#f2-jpr-11-1531}

![Comparison of visual analog scale (VAS) scores before and after treatment in the three groups.\
**Notes:** (**A**) Changes in low back pain VAS scores; (**B**) changes in radicular pain VAS scores. Results are presented as mean ± SD. Compared to before treatment, *\*P*\<0.05; group B compared to group A, ^∆^*P*\<0.05; group C compared to group A, ^†^*P*\<0.05; group C compared to group B, ^\#^*P*\<0.05.](jpr-11-1531Fig3){#f3-jpr-11-1531}

###### 

Likert scale 7-point scoring system: global perceived effect

  Score   Description      \% Change
  ------- ---------------- --------------------------------
  7       Very good        ≥75% improvement
  6       Good             ≥50% improvement
  5       Fairly good      ≥25% improvement
  4       Same as before   0 improvement or deterioration
  3       Fairly bad       ≥25% deterioration
  2       Bad              ≥50% deterioration
  1       Very bad         ≥75% deterioration

###### 

General condition of patients before treatment

  Parameters                      Group                 P                                           
  ------------------------------- --------------------- --------------------- --------------------- -------
  Patients (n)                    45                    45                    45                    --
  Gender (n, %)                                                                                     
   Female                         13 (28.9)             11 (24.4)             12 (26.7)             --
   Male                           32 (71.1)             34 (75.6)             33 (73.3)             --
  Age (years, range)              60.32±4.48 (53--65)   59.89±4.23 (52--66)   60.27±4.85 (51--68)   0.547
  Pain duration (months, range)   17.54±5.36 (12--29)   17.65±6.02 (11--27)   17.32±5.48 (11--30)   0.613
  Pain position (n, %)                                                                              
   Low back pain                  32 (71.1)             28 (62.2)             31 (68.9)             --
   Radicular pain                 45 (100)              45 (100)              45 (100)              --
  VAS score before treatment                                                                        
   Low back pain                  6.48±1.46             6.56±1.53             6.62±1.37             0.486
   Radicular pain                 7.13±1.03             7.07±1.21             7.18±1.15             0.452
  Side (n, %)                                                                                       
   Right                          27 (60)               27 (60)               28 (62.2)             --
   Left                           13 (28.9)             12 (26.7)             13 (28.9)             --
   Both                           5 (11.1)              6 (13.3)              4 (8.9)               --
  Treatment (WHO) (n, %)                                                                            
   WHO 1                          19 (42.2)             21 (46.7)             22 (48.9)             --
   WHO 2                          20 (44.5)             17 (37.8)             17 (37.8)             --
   WHO 3                          6 (13.3)              7 (15.5)              6 (13.3)              --

**Notes:** Data are presented as numbers (n, %) of patients or mean ± SD. Group A: TFESI; group B: PRF on spinal nerve root; group C: TFESI combined with PRF on spinal nerve root.

**Abbreviations:** VAS, visual analog scale; WHO, World Health Organization; TFESI, transforaminal epidural steroid injection; PRF, pulsed radio frequency.

###### 

Comparison of ODI before and after treatment in the three groups (%)

  Time               Group                                                    *P*-value                                                                                                                                                                                                                                                                                
  ------------------ -------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ --------- --------- ---------
  Before treatment   49.26±12.18                                              48.98±11.87                                                                                             49.15±12.32                                                                                                                                                  0.834     0.875     0.852
  After treatment                                                                                                                                                                                                                                                                                                                                                      
  1 day              35.58±7.97[\*](#tfn4-jpr-11-1531){ref-type="table-fn"}   41.23±8.23[\*](#tfn4-jpr-11-1531){ref-type="table-fn"},[\*\*](#tfn5-jpr-11-1531){ref-type="table-fn"}   35.26±8.02[\*](#tfn4-jpr-11-1531){ref-type="table-fn"},[\*\*\*\*](#tfn7-jpr-11-1531){ref-type="table-fn"}                                                    0.004     0.767     \<0.001
  14 days            33.63±6.14[\*](#tfn4-jpr-11-1531){ref-type="table-fn"}   32.87±6.45[\*](#tfn4-jpr-11-1531){ref-type="table-fn"}                                                  27.71±7.41[\*](#tfn4-jpr-11-1531){ref-type="table-fn"},[\*\*\*](#tfn6-jpr-11-1531){ref-type="table-fn"},[\*\*\*\*](#tfn7-jpr-11-1531){ref-type="table-fn"}   0.615     \<0.001   0.016
  1 month            32.29±6.01[\*](#tfn4-jpr-11-1531){ref-type="table-fn"}   31.17±5.98[\*](#tfn4-jpr-11-1531){ref-type="table-fn"}                                                  26.05±7.32[\*](#tfn4-jpr-11-1531){ref-type="table-fn"},[\*\*\*](#tfn6-jpr-11-1531){ref-type="table-fn"},[\*\*\*\*](#tfn7-jpr-11-1531){ref-type="table-fn"}   0.563     \<0.001   0.021
  3 months           31.18±6.46[\*](#tfn4-jpr-11-1531){ref-type="table-fn"}   24.52±5.23[\*](#tfn4-jpr-11-1531){ref-type="table-fn"},[\*\*](#tfn5-jpr-11-1531){ref-type="table-fn"}   23.18±5.21[\*](#tfn4-jpr-11-1531){ref-type="table-fn"},[\*\*\*](#tfn6-jpr-11-1531){ref-type="table-fn"}                                                      \<0.001   \<0.001   0.427
  6 months           29.39±4.67[\*](#tfn4-jpr-11-1531){ref-type="table-fn"}   21.56±5.19[\*](#tfn4-jpr-11-1531){ref-type="table-fn"},[\*\*](#tfn5-jpr-11-1531){ref-type="table-fn"}   20.23±4.16[\*](#tfn4-jpr-11-1531){ref-type="table-fn"},[\*\*\*](#tfn6-jpr-11-1531){ref-type="table-fn"}                                                      \<0.001   \<0.001   0.453

**Notes:** Data are presented as mean ± SD (%). Group A: TFESI; group B: PRF on spinal nerve root; group C: TFESI combined with PRF on spinal nerve root. Compared to before treatment,

*P*\<0.05; group A compared to group B,

*P*\<0.05; group C compared to group A,

*P*\<0.05; group C compared to group B,

*P*\<0.05.

**Abbreviations:** ODI, Oswestry disability index; TFESI, transforaminal epidural steroid injection; PRF, pulsed radio frequency.

###### 

Comparison of GPE after treatment in the three groups (n, %)

  Time       Group       *P*-value                                                                                                                                                                             
  ---------- ----------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------- ------- -------
  1 day      34 (75.6)   25 (55.6)[\*](#tfn10-jpr-11-1531){ref-type="table-fn"}   35 (77.8)[\*\*\*](#tfn12-jpr-11-1531){ref-type="table-fn"}                                                   0.046   0.803   0.025
  14 days    28 (62.2)   26 (57.8)                                                37 (82.2)[\*\*](#tfn11-jpr-11-1531){ref-type="table-fn"},[\*\*\*](#tfn12-jpr-11-1531){ref-type="table-fn"}   0.667   0.034   0.011
  1 month    25 (55.6)   28 (62.2)                                                37 (82.2)[\*\*](#tfn11-jpr-11-1531){ref-type="table-fn"},[\*\*\*](#tfn12-jpr-11-1531){ref-type="table-fn"}   0.520   0.006   0.034
  3 months   20 (44.4)   30 (66.7)[\*](#tfn10-jpr-11-1531){ref-type="table-fn"}   32 (71.1)[\*\*](#tfn11-jpr-11-1531){ref-type="table-fn"}                                                     0.034   0.010   0.649
  6 months   18 (40.0)   28 (62.2)[\*](#tfn10-jpr-11-1531){ref-type="table-fn"}   29 (64.4)[\*\*](#tfn11-jpr-11-1531){ref-type="table-fn"}                                                     0.035   0.020   0.827

**Notes:** GPE results: percentages of patients with score ≥6. Data are presented as numbers (%) of patients. Group A: TFESI; group B: PRF on spinal nerve root; group C: TFESI combined with PRF on spinal nerve root. Group A compared to group B,

*P*\<0.05; group C compared to group A,

*P*\<0.05; group C compared to group B,

*P*\<0.05.

**Abbreviations:** GPE, global perceived effect; TFESI, transforaminal epidural steroid injection.
